Antibodies against complement-regulatory proteins on platelets in immune thrombocytopenia

References

• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–186.
   Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346(13):995–1008.
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C. Idiopathic thrombocytopenic purpura (ITP): Clinical and immunologic considerations. Semin Thromb Hemost 1977;3(3):125–159.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994;331(18):1207–1211.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kunicki TJ, Michelson AD. Platelets: New understanding of platelet glycoproteins and their role in disease. Hematology Am Soc Hematol Educ Program 2000:2000(1)222–240.
   PubMedGoogle Scholar
• McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods VL, Jr. Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 1987;70(4):1040–1045.
   PubMed Web of Science ®Google Scholar
• Kiefel V, Santoso S, Kaufmann E, Mueller-Eckhardt C. Autoantibodies against platelet glycoprotein Ib/IX: A frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 1991;79(2):256–262.
   PubMed Web of Science ®Google Scholar
• Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Evidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1995;90(1):175–179.
   PubMed Web of Science ®Google Scholar
• Kiefel V, Freitag E, Kroll H, Santoso S, Mueller-Eckhardt C. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996;72(4):280–285.
   PubMed Web of Science ®Google Scholar
• Hou M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): Evidence for at least two different IgG antibodies. Br J Haematol 1997;98(1):64–67.
   PubMed Web of Science ®Google Scholar
• Frelinger AL, 3rd, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015;126(7):873–879.
   Google Scholar
• Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol 2012;19(5):357–362.
   Google Scholar
• Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9(9):1123–1124.
   PubMed Web of Science ®Google Scholar
• Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986;63(2):293–300.
   PubMed Web of Science ®Google Scholar
• Panzer S, Niessner H, Lechner K, Dudczak R, Jager U, Mayr WR. Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3c in chronic idiopathic autoimmune thrombocytopenia: Relation to the sequestration pattern of 111indium labelled platelets. Scand J Haematol 1986;37(2):97–102.
   PubMedGoogle Scholar
• Panzer S, Szamait S, Bodeker RH, Haas OA, Haubenstock A, Mueller-Eckhardt C. Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders. Am J Hematol 1986;23(2):89–99.
   PubMed Web of Science ®Google Scholar
• Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010;148(4):638–645.
   Google Scholar
• Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, Sachs UJ. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 2012;88(2):167–174.
   Google Scholar
• Nicholson-Weller A. Decay accelerating factor (CD55). Curr Top Microbiol Immunol 1992;178:7–30.
   PubMed Web of Science ®Google Scholar
• Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71(1):1–9.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Young NS, Yu M, Anderson SM, Sloand EM. Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thromb Res 1996;83(6):433–447.
   PubMed Web of Science ®Google Scholar
• Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008;19(3):225–233.
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, March JP, Rosen CE, Spicer DB, Austen KF. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 1985;65(5):1237–1244.
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25(11):1256–1264.
   PubMed Web of Science ®Google Scholar
• Risitano AM. Anti-complement treatment in paroxysmal nocturnal hemoglobinuria: Where we stand and where we are going. Transl Med UniSa 2014;8:43–52.
   PubMedGoogle Scholar
• Nguyen XD, Dugrillon A, Beck C, Kerowgan M, Kluter H. A novel method for simultaneous analysis of specific platelet antibodies: SASPA. Br J Haematol 2004;127(5):552–560.
   PubMed Web of Science ®Google Scholar
• Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody–specific immobilization of platelet antigens (MAIPA): A new tool for the identification of platelet-reactive antibodies. Blood 1987;70(6):1722–1726.
   PubMed Web of Science ®Google Scholar